RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, announced today the close of a $15 million Series A financing co-led by SPRIM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback